Liraglutide Cost in Wisconsin 2026: Prices, Insurance, Medicaid and Compounding

What Does Liraglutide Actually Cost in Wisconsin Right Now?

Wisconsin patients paying cash for liraglutide face a wide price range depending on the source. Brand Saxenda and Victoza carry a Novo Nordisk list price of $1,349 per month in 2026. Retail pharmacies across Wisconsin average roughly $900 per month after typical pharmacy-level discounts, and licensed 503A compounding pharmacies offer compounded liraglutide for approximately $150 per month.

That three-tier spread matters because it determines which patients can realistically stay on therapy long enough to see results. The SCALE Obesity trial published in the New England Journal of Medicine (N=3,731) showed that participants taking liraglutide 3.0 mg daily lost a mean 8.4% more body weight than placebo at 56 weeks, with 63.2% achieving at least 5% weight loss [1]. Sustaining that outcome requires months of consistent dosing, so affordability is a direct clinical variable, not just a billing detail.

The FDA approved liraglutide 3.0 mg (Saxenda) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with at least one weight-related comorbidity [2]. Liraglutide 1.2 mg and 1.8 mg (Victoza) carry a separate approval for glycemic control in type 2 diabetes [2]. Prices differ modestly between formulations at retail, but the compounded route applies to both indications.

Pharmacy benefit managers often negotiate rebates that reduce the effective payer cost below list price, but those savings rarely flow to cash-pay patients at the counter. Patients without insurance or with high-deductible plans almost always pay closer to the $900 retail figure unless they use a manufacturer savings card, a coupon aggregator like GoodRx, or a compounding pharmacy [3].

GLP-1 receptor agonists including liraglutide work by mimicking endogenous glucagon-like peptide-1, slowing gastric emptying, reducing appetite, and stimulating glucose-dependent insulin secretion [4]. The American Diabetes Association 2024 Standards of Care list liraglutide as a preferred agent in type 2 diabetes with established cardiovascular disease, citing the LEADER trial (N=9,340), which found a 13% relative reduction in major adverse cardiovascular events versus placebo (hazard ratio 0.87 to 95% CI 0.78-0.97, P<0.001 for noninferiority and P=0.01 for superiority) [5].

Wisconsin Medicaid Coverage for Liraglutide

Wisconsin Medicaid covers liraglutide for both type 2 diabetes and chronic weight management, but prior authorization (PA) is required for both indications. The PA process typically takes two to five business days once a complete request is submitted, and denials can be appealed through the ForwardHealth portal.

For the obesity indication, Wisconsin ForwardHealth generally requires documentation of a BMI ≥30 (or ≥27 with a qualifying comorbidity), failure of a structured behavioral intervention of at least six months, and absence of contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. The Endocrine Society Clinical Practice Guideline on obesity pharmacotherapy specifies that drug therapy should be considered only as an adjunct to lifestyle modification, a criterion Wisconsin Medicaid reflects in its PA criteria [6].

Patients on Wisconsin Medicaid should ask their provider to document all required criteria in the PA letter before submission. Missing a single element, such as the structured lifestyle intervention, is the most common reason for first-round denial. A peer-to-peer call between the prescribing clinician and the Medicaid medical director resolves most denials within 72 hours.

For the diabetes indication, PA requirements center on confirming a type 2 (not type 1) diagnosis, an HbA1c above the plan threshold (commonly 7.5-8.0%), and inadequate control on metformin or another first-line agent. The American Association of Clinical Endocrinology 2022 diabetes algorithm recommends GLP-1 receptor agonists as second-line therapy after metformin for most patients with type 2 diabetes, particularly those with overweight or obesity [7].

Wisconsin BadgerCare Plus, the state's Medicaid expansion plan, follows the same ForwardHealth drug policy. Low-income adults who qualify for BadgerCare Plus and meet PA criteria pay $0 to $3 copays per prescription once approved, making Medicaid by far the lowest net cost option for eligible Wisconsin residents [8].

Is Compounded Liraglutide Legal in Wisconsin?

Compounded liraglutide is legally available in Wisconsin through state-licensed 503A pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drug products for identified individual patients based on a valid prescription from a licensed practitioner, provided the compound is not essentially a copy of a commercially available product [9].

Liraglutide occupies a gray zone here. The FDA has not placed liraglutide on the shortage list the way it did with semaglutide in 2022-2024, so 503B outsourcing facilities face stricter restrictions on bulk compounding of liraglutide than they did for semaglutide during the shortage period. Individual patient-specific compounding under 503A remains permissible in Wisconsin as long as the pharmacy holds a current Wisconsin Pharmacy Examining Board license, the prescription is patient-specific, and the compounded preparation differs meaningfully from the commercial product (for example, in concentration, delivery device, or excipient profile) [10].

Patients and prescribers should verify that any Wisconsin 503A pharmacy dispensing compounded liraglutide is in good standing with the Wisconsin Department of Safety and Professional Services and is compliant with USP <797> sterile compounding standards [11]. The FDA has issued warning letters to 503A and 503B facilities compounding GLP-1 peptides with inadequate quality controls, so due diligence matters [12].

At approximately $150 per month, compounded liraglutide is roughly six times cheaper than the average Wisconsin retail cash price for branded product. The pharmacoeconomic argument is straightforward: a patient who cannot afford $900 per month will discontinue therapy, losing all clinical benefit. A compound at $150 per month sustained over 56 weeks costs roughly $2,100 total, compared with $50,400 for brand at list price over the same period.

The trade-off is that compounded preparations are not FDA-approved and lack the post-market surveillance and lot-release testing that Novo Nordisk applies to Saxenda and Victoza. The decision to use a compounded product should involve an explicit conversation between the patient and the prescribing clinician, and prescribers should document that discussion in the chart [9].

Which Insurance Plans Cover Liraglutide in Wisconsin?

Coverage varies substantially by plan type, and the Wisconsin insurance market includes employer-sponsored plans, ACA marketplace plans, Medicare Part D, and Medicaid.

Employer-sponsored plans follow federal rules and each employer's pharmacy benefit design. Many large self-insured employers in Wisconsin exclude anti-obesity medications (AOMs) from their formularies following longstanding ERISA plan design conventions, though this is slowly changing as employers recognize the downstream cost offsets of treated obesity. Liraglutide for type 2 diabetes (Victoza) is more consistently covered than Saxenda for obesity across employer plans [13].

ACA marketplace plans in Wisconsin are not required to cover anti-obesity medications under the ACA's essential health benefits benchmark unless the state benchmark plan includes them. Wisconsin's benchmark does not mandate AOM coverage as of 2026, so coverage is plan-specific. Victoza for diabetes is more reliably on formulary than Saxenda for weight management [14].

Medicare Part D has historically excluded weight-loss drugs under the Social Security Act, but the Treat and Reduce Obesity Act, if enacted, would change that. As of 2026, Victoza (diabetes indication) is covered under Part D, while Saxenda (obesity indication) is excluded for most Part D beneficiaries. Patients with Medicare should confirm their plan's formulary tier for Victoza, as cost-sharing ranges from roughly $35 to $200 per month depending on the plan and the phase of the benefit [15].

Wisconsin Medicaid, as described above, covers both indications with PA. This is the most generous coverage option for eligible patients.

Patients with commercial insurance should request a formulary exception letter from their clinician if liraglutide is not on formulary, particularly when there is documented cardiovascular disease and liraglutide is the clinician's preferred agent based on LEADER trial evidence [5]. The Endocrine Society notes that cardiovascular benefit data should be included in any formulary exception request for GLP-1 agents [6].

Manufacturer Savings Cards and Other Wisconsin Discount Programs

Novo Nordisk operates savings card programs for both Saxenda and Victoza that can substantially reduce out-of-pocket costs for commercially insured patients who do not qualify for government coverage.

The Saxenda Savings Card (for adults with commercial insurance) can reduce monthly cost-sharing to as low as $25 per fill for eligible patients, with a maximum annual savings cap that Novo Nordisk updates each year. Patients must be commercially insured; the card is not valid for Medicare, Medicaid, or other federal programs [16].

The Victoza My$avings Card operates similarly for the diabetes formulation. Eligible commercially insured patients in Wisconsin can use it at any participating retail pharmacy in the state [16].

GoodRx and similar coupon platforms aggregate pharmacy-negotiated prices and can bring the Wisconsin retail cash price for Victoza from $900 to approximately $700-850 per month depending on the pharmacy chain and specific coupon. GoodRx coupons cannot be used with insurance simultaneously; patients choose one or the other per fill.

NeedyMeds and Novo Nordisk's Patient Assistance Program (PAP) provide free or heavily discounted medication to uninsured or underinsured patients whose household income falls below program thresholds, typically 400% of the federal poverty level for manufacturer PAPs. Wisconsin patients can apply directly through the Novo Nordisk patient assistance portal or through a social worker at their clinic [17].

The Wisconsin Association of Free and Charitable Clinics connects uninsured patients to free clinic networks that may stock sample medications or have direct PAP relationships with Novo Nordisk. Clinicians at those sites can sometimes dispense samples while the PAP application is processed, bridging a gap that otherwise leads to early discontinuation.

Telehealth Prescribing of Liraglutide in Wisconsin

Liraglutide can be legally prescribed via telehealth in Wisconsin. The state's telehealth parity law (Wis. Stat. 632.895(17)) requires commercial insurers to reimburse telehealth services at parity with in-person visits, and Wisconsin Medicaid (ForwardHealth) covers synchronous audio-video telehealth encounters for covered services including evaluation and management visits [18].

A Wisconsin-licensed prescriber conducting a telehealth encounter must complete an appropriate medical evaluation before prescribing any controlled or non-controlled prescription medication. Liraglutide is not a controlled substance, so it does not trigger the additional restrictions that apply to, for example, stimulants or benzodiazepines. A clinician may prescribe liraglutide after a synchronous audio-video visit that includes review of the patient's BMI, medical history, contraindications, and labs, provided the encounter meets the standard of care for an in-person evaluation [19].

The DEA's 2023 telehealth prescribing rule primarily affects controlled substances and does not restrict liraglutide prescribing via telehealth. Wisconsin practitioners can therefore initiate Saxenda or Victoza therapy for an established or new telehealth patient without requiring an in-person visit first [19].

For obesity management, the American Obesity Association has noted that telehealth access to GLP-1 medications reduces a significant access barrier in rural Wisconsin, where endocrinology and obesity medicine specialists are scarce. Roughly 68% of Wisconsin counties have fewer than one obesity medicine specialist per 50,000 residents, based on American Board of Obesity Medicine diplomate data [20].

How Liraglutide Compares Clinically to Other GLP-1 Options Available in Wisconsin

Wisconsin clinicians and patients choosing among GLP-1 therapies have several options at different price points and efficacy tiers. Liraglutide remains clinically relevant despite the availability of higher-efficacy agents.

In the SCALE Obesity trial (N=3,731), liraglutide 3.0 mg produced 8.4% greater weight loss than placebo at 56 weeks, with 63.2% of participants losing 5% or more body weight [1]. By comparison, the STEP-1 trial of semaglutide 2.4 mg (N=1,961) showed 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [21]. Tirzepatide (SURMOUNT-1, N=2,539) produced up to 22.5% mean weight loss at 72 weeks on the 15 mg dose [22].

Liraglutide is therefore a lower-efficacy agent than semaglutide or tirzepatide for weight management, but it has a well-established safety record spanning more than a decade of post-market use, a once-daily injection schedule that some patients prefer over once-weekly regimens, and substantially lower compounded cost in Wisconsin. For patients who fail liraglutide after an adequate trial (defined as less than 4% weight loss after 16 weeks at the 3.0 mg dose, per the Saxenda prescribing information), escalation to semaglutide or tirzepatide is appropriate [2].

The LEADER cardiovascular outcomes trial demonstrated that liraglutide reduced three-point MACE by 13% versus placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.87 to 95% CI 0.78-0.97) [5]. This cardiovascular benefit remains a strong clinical rationale for choosing liraglutide over other diabetes agents in appropriate Wisconsin patients, particularly when cost is not the limiting factor or when Medicaid coverage is secured.

Nausea is the most common adverse effect across the dose-escalation period, occurring in approximately 40% of participants in SCALE Obesity during the first 12 weeks [1]. Dose escalation from 0.6 mg to 3.0 mg over five weeks, as specified in the FDA label, reduces nausea severity [2]. Pancreatitis risk is rare but real; liraglutide carries an FDA boxed warning for thyroid C-cell tumors observed in rodent studies, and the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 [2].

Step-by-Step Guide: Getting Liraglutide at the Lowest Cost in Wisconsin

A Wisconsin patient seeking liraglutide at the lowest sustainable cost should work through the following decision path, starting with coverage eligibility before selecting a pharmacy source.

Step 1: Confirm eligibility for Wisconsin Medicaid or BadgerCare Plus. Patients with household incomes at or below 138% of the federal poverty level likely qualify for BadgerCare Plus, which covers liraglutide with PA at minimal or no copay. Income eligibility tools are available at access.wi.gov [8].

Step 2: Check employer or marketplace insurance formulary. If insured, request the plan's formulary tier for both Saxenda (NDC 00169-4060-12) and Victoza (NDC 00169-4137-11) and the PA criteria. If the diabetes indication applies, Victoza is more likely to be covered than Saxenda.

Step 3: Apply the manufacturer savings card if commercially insured. Novo Nordisk savings cards require commercial insurance and can cut monthly cost to $25 for qualifying patients [16].

Step 4: Compare GoodRx prices at Wisconsin pharmacies. Prices vary by up to $150 per month between pharmacy chains in major Wisconsin markets including Milwaukee, Madison, Green Bay, and Appleton.

Step 5: Evaluate a licensed Wisconsin 503A compounding pharmacy if cash-pay. If no coverage exists and savings cards do not apply, a licensed 503A compound at $150 per month may be the only option that sustains long-term adherence. Verify the pharmacy's Wisconsin license and USP <797> compliance before filling [10].

Step 6: Apply for the Novo Nordisk PAP if uninsured and income-eligible. Applications take two to four weeks to process; clinicians should bridge with samples where available [17].

A clinician-guided telehealth visit through HealthRX can handle PA submissions, savings card enrollment, and compounding pharmacy referral in a single encounter, reducing the administrative burden that causes many Wisconsin patients to abandon liraglutide before the therapeutic window opens. Patients who remain on liraglutide 3.0 mg for at least 16 weeks and lose less than 4% of body weight should be reassessed for dose adequacy or transition to a higher-efficacy GLP-1 agent [2].